Download PDF
Thromb Haemost 2018; 118(10): 1803-1814
DOI: 10.1055/s-0038-1669922
Cellular Signalling and Proteolysis
Georg Thieme Verlag KG Stuttgart · New York

Pro-Angiogenic Effects of Latent Heparanase and Thrombin Receptor-Mediated Pathways—Do They Share a Common Ground in Melanoma Cells?

Sebastian G. Hoß
1   Department of Pharmacy, University of Bonn, Bonn, Germany
,
Manuel Grundmann
2   Molecular, Cellular and Pharmacobiology Section, Institute for Pharmaceutical Biology, University of Bonn, Bonn, Germany
3   Cardiovascular Research, Bayer AG, Pharma Research Center, Wuppertal, Germany
,
Tobias Benkel
2   Molecular, Cellular and Pharmacobiology Section, Institute for Pharmaceutical Biology, University of Bonn, Bonn, Germany
,
Lukas Gockel
1   Department of Pharmacy, University of Bonn, Bonn, Germany
,
Svenja Schwarz
1   Department of Pharmacy, University of Bonn, Bonn, Germany
,
Evi Kostenis
2   Molecular, Cellular and Pharmacobiology Section, Institute for Pharmaceutical Biology, University of Bonn, Bonn, Germany
,
Martin Schlesinger
1   Department of Pharmacy, University of Bonn, Bonn, Germany
,
Neta Ilan
4   Cancer and Vascular Biology Research Center, Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
,
Israel Vlodavsky
4   Cancer and Vascular Biology Research Center, Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
,
Gerd Bendas
1   Department of Pharmacy, University of Bonn, Bonn, Germany
› Author Affiliations
Further Information

Publication History

07 May 2018

06 August 2018

Publication Date:
20 September 2018 (online)

Also available at
    Permissions and Reprints

Abstract

Heparanase (HPSE) is an endo-β-D-glucuronidase that cleaves heparan sulphate (HS) chains of proteoglycans (HSPGs). Besides a remodelling of the extracellular matrix, HPSE increases the bioavailability of pro-angiogenic mediators, such as HS-associated vascular endothelial growth factor (VEGF), thereby contributing to metastatic niche formation. Notably, HPSE also induces release of VEGF from tumour cells independent of its enzymatic activity, but the underlying molecular mechanisms remain unresolved. We found that exogenous addition of latent HPSE stimulates VEGF release from human MV3 melanoma cells. The same effect was noted upon direct stimulation of thrombin receptor (protease-activated receptor 1 [PAR-1]) by Thrombin Receptor Activator Peptide 6 (TRAP-6). The matricellular ligand cysteine-rich 61 protein (Cyr61) was identified as pathway component since Cyr61 knockdown in MV3 cells abolished the VEGF release by TRAP-6 and HPSE. Since both TRAP-6 and HPSE mediated an up-regulation of phosphorylated focal adhesion kinase, which could be blocked by antagonizing PAR-1, we postulated a crosstalk between latent HPSE and PAR-1 in promoting pro-angiogenic pathways. To test this hypothesis at a molecular level, we applied dynamic mass redistribution (DMR) technique measuring intracellular mass relocation as consequence of direct receptor activation. Indeed, latent HPSE evoked a concentration-dependent DMR signal in MV3 cells as TRAP-6 did. Both could be modulated by targeting G-protein receptor signalling in general or by the PAR-1 inhibitor RWJ 56110. Using cells devoid of cell surface HS synthesis, we could confirm HPSE effects on PAR-1, independent of HSPG involvement. These data indicate, for the first time, a crosstalk between latent HPSE, thrombin receptor activation and G-protein signalling in general.

Keywords

heparanase - metastatic niche - PAR-1 - tumour - vascular endothelial growth factor

Authors' Contributions

S.G.H. performed the experiments, analysed the data and co-wrote the manuscript. M.G., T.B. and L.M.G. assisted in the performance of the DMR biosensor measurements and analysis of the data. S.S. performed the platelet experiments. E.K. designed the DMR analysis and data evaluation. M.S. designed the experiments and co-wrote the manuscript. N.I. and I.V. prepared and supplied the HPSE and designed experiments and G.B. designed the experiments and wrote the article.


Supplementary Material

 

  • References

  • 1 Vlodavsky I, Friedmann Y, Elkin M. , et al. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med 1999; 5 (07) 793-802
    CrossrefPubMedGoogle Scholar
  • 2 Vlodavsky I, Elkin M, Abboud-Jarrous G. , et al. Heparanase: one molecule with multiple functions in cancer progression. Connect Tissue Res 2008; 49 (03) 207-210
    CrossrefPubMedGoogle Scholar
  • 3 Vornicova O, Naroditsky I, Boyango I. , et al. Prognostic significance of heparanase expression in primary and metastatic breast carcinoma. Oncotarget 2017; 9 (05) 6238-6244
    PubMedGoogle Scholar
  • 4 Hu J, Wang J, Leng X, Hu Y, Shen H, Song X. Heparanase mediates vascular endothelial growth factor gene transcription in high-glucose human retinal microvascular endothelial cells. Mol Vis 2017; 23: 579-587
    PubMedGoogle Scholar
  • 5 Cohen-Kaplan V, Naroditsky I, Zetser A, Ilan N, Vlodavsky I, Doweck I. Heparanase induces VEGF C and facilitates tumor lymphangiogenesis. Int J Cancer 2008; 123 (11) 2566-2573
    CrossrefPubMedGoogle Scholar
  • 6 Zetser A, Bashenko Y, Edovitsky E, Levy-Adam F, Vlodavsky I, Ilan N. Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res 2006; 66 (03) 1455-1463
    CrossrefPubMedGoogle Scholar
  • 7 Goubran HA, Stakiw J, Radosevic M, Burnouf T. Platelet-cancer interactions. Semin Thromb Hemost 2014; 40 (03) 296-305
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Dupuy E, Habib A, Lebret M, Yang R, Levy-Toledano S, Tobelem G. Thrombin induces angiogenesis and vascular endothelial growth factor expression in human endothelial cells: possible relevance to HIF-1alpha. J Thromb Haemost 2003; 1 (05) 1096-1102
    CrossrefPubMedGoogle Scholar
  • 9 Nierodzik ML, Karpatkin S. Thrombin induces tumor growth, metastasis, and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 2006; 10 (05) 355-362
    CrossrefPubMedGoogle Scholar
  • 10 Lau LF. Cell surface receptors for CCN proteins. J Cell Commun Signal 2016; 10 (02) 121-127
    CrossrefPubMedGoogle Scholar
  • 11 Lau LF. CCN1/CYR61: the very model of a modern matricellular protein. Cell Mol Life Sci 2011; 68 (19) 3149-3163
    CrossrefPubMedGoogle Scholar
  • 12 Walsh CT, Radeff-Huang J, Matteo R. , et al. Thrombin receptor and RhoA mediate cell proliferation through integrins and cysteine-rich protein 61. FASEB J 2008; 22 (11) 4011-4021
    CrossrefPubMedGoogle Scholar
  • 13 Walsh CT, Stupack D, Brown JH. G protein-coupled receptors go extracellular: RhoA integrates the integrins. Mol Interv 2008; 8 (04) 165-173
    CrossrefPubMedGoogle Scholar
  • 14 De S, Razorenova O, McCabe NP, O'Toole T, Qin J, Byzova TV. VEGF-integrin interplay controls tumor growth and vascularization. Proc Natl Acad Sci U S A 2005; 102 (21) 7589-7594
    CrossrefPubMedGoogle Scholar
  • 15 Nadir Y, Brenner B, Fux L, Shafat I, Attias J, Vlodavsky I. Heparanase enhances the generation of activated factor X in the presence of tissue factor and activated factor VII. Haematologica 2010; 95 (11) 1927-1934
    CrossrefPubMedGoogle Scholar
  • 16 Crispel Y, Axelman E, Tatour M. , et al. Peptides inhibiting heparanase procoagulant activity significantly reduce tumour growth and vascularisation in a mouse model. Thromb Haemost 2016; 116 (04) 669-678
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Katz B-Z, Muhl L, Zwang E. , et al. Heparanase modulates heparinoids anticoagulant activities via non-enzymatic mechanisms. Thromb Haemost 2007; 98 (06) 1193-1199
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Playford MP, Schaller MD. The interplay between Src and integrins in normal and tumor biology. Oncogene 2004; 23 (48) 7928-7946
    CrossrefPubMedGoogle Scholar
  • 19 Riaz A, Ilan N, Vlodavsky I, Li J-P, Johansson S. Characterization of heparanase-induced phosphatidylinositol 3-kinase-AKT activation and its integrin dependence. J Biol Chem 2013; 288 (17) 12366-12375
    CrossrefPubMedGoogle Scholar
  • 20 Jung O, Trapp-Stamborski V, Purushothaman A. , et al. Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins. Oncogenesis 2016; 5: e202
    CrossrefPubMedGoogle Scholar
  • 21 Zetser A, Bashenko Y, Miao H-Q, Vlodavsky I, Ilan N. Heparanase affects adhesive and tumorigenic potential of human glioma cells. Cancer Res 2003; 63 (22) 7733-7741
    PubMedGoogle Scholar
  • 22 Schmitz P, Gerber U, Schütze N. , et al. Cyr61 is a target for heparin in reducing MV3 melanoma cell adhesion and migration via the integrin VLA-4. Thromb Haemost 2013; 110 (05) 1046-1054
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Schröder R, Schmidt J, Blättermann S. , et al. Applying label-free dynamic mass redistribution technology to frame signaling of G protein-coupled receptors noninvasively in living cells. Nat Protoc 2011; 6 (11) 1748-1760
    CrossrefPubMedGoogle Scholar
  • 24 Zigler M, Kamiya T, Brantley EC, Villares GJ, Bar-Eli M. PAR-1 and thrombin: the ties that bind the microenvironment to melanoma metastasis. Cancer Res 2011; 71 (21) 6561-6566
    CrossrefPubMedGoogle Scholar
  • 25 Tatour M, Shapira M, Axelman E. , et al. Thrombin is a selective inducer of heparanase release from platelets and granulocytes via protease-activated receptor-1. Thromb Haemost 2017; 117 (07) 1391-1401
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Leu S-J, Lam SC-T, Lau LF. Pro-angiogenic activities of CYR61 (CCN1) mediated through integrins alphavbeta3 and alpha6beta1 in human umbilical vein endothelial cells. J Biol Chem 2002; 277 (48) 46248-46255
    CrossrefPubMedGoogle Scholar
  • 27 Chen N, Leu S-J, Todorovic V, Lam SC-T, Lau LF. Identification of a novel integrin alphavbeta3 binding site in CCN1 (CYR61) critical for pro-angiogenic activities in vascular endothelial cells. J Biol Chem 2004; 279 (42) 44166-44176
    CrossrefPubMedGoogle Scholar
  • 28 Habel N, Vilalta M, Bawa O, Opolon P, Blanco J, Fromigué O. Cyr61 silencing reduces vascularization and dissemination of osteosarcoma tumors. Oncogene 2015; 34 (24) 3207-3213
    CrossrefPubMedGoogle Scholar
  • 29 Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407 (6801): 258-264
    CrossrefPubMedGoogle Scholar
  • 30 Soh UJK, Dores MR, Chen B, Trejo J. Signal transduction by protease-activated receptors. Br J Pharmacol 2010; 160 (02) 191-203
    CrossrefPubMedGoogle Scholar
  • 31 Mangmool S, Kurose H. G(i/o) protein-dependent and -independent actions of Pertussis Toxin (PTX). Toxins (Basel) 2011; 3 (07) 884-899
    CrossrefPubMedGoogle Scholar
  • 32 Pala D, Rivara S, Mor M. , et al. Kinetic analysis and molecular modeling of the inhibition mechanism of roneparstat (SST0001) on human heparanase. Glycobiology 2016; 26 (06) 640-654
    CrossrefPubMedGoogle Scholar
  • 33 Ni M, Elli S, Naggi A, Guerrini M, Torri G, Petitou M. Investigating glycol-split-heparin-derived inhibitors of heparanase: a study of synthetic trisaccharides. Molecules 2016; 21 (11) E1602
    CrossrefPubMedGoogle Scholar
  • 34 Esko JD, Stewart TE, Taylor WH. Animal cell mutants defective in glycosaminoglycan biosynthesis. Proc Natl Acad Sci U S A 1985; 82 (10) 3197-3201
    CrossrefPubMedGoogle Scholar
  • 35 Esko JD, Rostand KS, Weinke JL. Tumor formation dependent on proteoglycan biosynthesis. Science 1988; 241 (4869): 1092-1096
    CrossrefPubMedGoogle Scholar
  • 36 Michael KE, Dumbauld DW, Burns KL, Hanks SK, García AJ. Focal adhesion kinase modulates cell adhesion strengthening via integrin activation. Mol Biol Cell 2009; 20 (09) 2508-2519
    CrossrefPubMedGoogle Scholar
  • 37 Claesson-Welsh L, Welsh M. VEGFA and tumour angiogenesis. J Intern Med 2013; 273 (02) 114-127
    CrossrefPubMedGoogle Scholar
  • 38 You J-J, Yang C-H, Yang C-M, Chen M-S. Cyr61 induces the expression of monocyte chemoattractant protein-1 via the integrin ανβ3, FAK, PI3K/Akt, and NF-κB pathways in retinal vascular endothelial cells. Cell Signal 2014; 26 (01) 133-140
    CrossrefPubMedGoogle Scholar
  • 39 Di Y, Zhang Y, Yang H, Wang A, Chen X. The mechanism of CCN1-enhanced retinal neovascularization in oxygen-induced retinopathy through PI3K/Akt-VEGF signaling pathway. Drug Des Devel Ther 2015; 9: 2463-2473
    PubMedGoogle Scholar
  • 40 Bandari SK, Purushothaman A, Ramani VC. , et al. Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior. Matrix Biol 2018; 65: 104-118
    CrossrefPubMedGoogle Scholar
  • 41 Weidle UH, Birzele F, Kollmorgen G, Rüger R. The multiple roles of exosomes in metastasis. Cancer Genomics Proteomics 2017; 14 (01) 1-15
    CrossrefPubMedGoogle Scholar
  • 42 Roucourt B, Meeussen S, Bao J, Zimmermann P, David G. Heparanase activates the syndecan-syntenin-ALIX exosome pathway. Cell Res 2015; 25 (04) 412-428
    CrossrefPubMedGoogle Scholar
  • 43 Vlodavsky I, Gross-Cohen M, Weissmann M, Ilan N, Sanderson RD. Opposing functions of heparanase-1 and heparanase-2 in cancer progression. Trends Biochem Sci 2018; 43 (01) 18-31
    CrossrefPubMedGoogle Scholar
  • 44 Goldshmidt O, Zcharia E, Cohen M. , et al. Heparanase mediates cell adhesion independent of its enzymatic activity. FASEB J 2003; 17 (09) 1015-1025
    CrossrefPubMedGoogle Scholar
  • 45 Levy-Adam F, Feld S, Suss-Toby E, Vlodavsky I, Ilan N. Heparanase facilitates cell adhesion and spreading by clustering of cell surface heparan sulfate proteoglycans. PLoS One 2008; 3 (06) e2319
    CrossrefPubMedGoogle Scholar
  • 46 Gerber U, Hoß SG, Shteingauz A. , et al. Latent heparanase facilitates VLA-4-mediated melanoma cell binding and emerges as a relevant target of heparin in the interference with metastatic progression. Semin Thromb Hemost 2015; 41 (02) 244-254
    Article in Thieme ConnectPubMedGoogle Scholar
  • 47 Nadir Y, Brenner B, Zetser A. , et al. Heparanase induces tissue factor expression in vascular endothelial and cancer cells. J Thromb Haemost 2006; 4 (11) 2443-2451
    CrossrefPubMedGoogle Scholar
  • 48 Nadir Y, Brenner B, Gingis-Velitski S. , et al. Heparanase induces tissue factor pathway inhibitor expression and extracellular accumulation in endothelial and tumor cells. Thromb Haemost 2008; 99 (01) 133-141
    Article in Thieme ConnectPubMedGoogle Scholar
  • 49 Ceruso MA, McComsey DF, Leo GC. , et al. Thrombin receptor-activating peptides (TRAPs): investigation of bioactive conformations via structure-activity, spectroscopic, and computational studies. Bioorg Med Chem 1999; 7 (11) 2353-2371
    CrossrefPubMedGoogle Scholar
  • 50 Grishina Z, Ostrowska E, Halangk W, Sahin-Tóth M, Reiser G. Activity of recombinant trypsin isoforms on human proteinase-activated receptors (PAR): mesotrypsin cannot activate epithelial PAR-1, -2, but weakly activates brain PAR-1. Br J Pharmacol 2005; 146 (07) 990-999
    CrossrefPubMedGoogle Scholar